LNG-IUS for Treatment of Dysmenorrhea

Learn more about:
Related Clinical Trial
The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis Long-term Use of Mifepristone in the Treatment of Adenomyosis Radiofrequency Ablation of Adenomyosis Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis The Effect of Adenomoyosis on Pregnancy Outcomes Observational Study of Patients Suffering From Endometriosis and Adenomyosis Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Quality of Life After Hysterectomy (AdenoQOL) Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI Clinical and Molecular Study of Endometriosis and Adenomyosis Surgical Success After Laparoscopic vs Abdominal Hysterectomy Electronic Catheter Stethoscope Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Uterine Artery Embolization for Symptomatic Fibroids Oxytocin in MRI-HIFU To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Effect of Addition of Steroids on Duration of Analgesia Paracervical Block in Laparoscopic Hysterectomy Use of Dexamethasone in Uterine Artery Embolization Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Dienogest for Treatment of Adenomyotic Uteri Health-Related QoL Among Women Receiving Hysterectomy in NTUH Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Adenomyosis and Ulipristal Acetate Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis LNG-IUS for Treatment of Dysmenorrhea Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Adenomyosis: Genomic Mechanisms and Biological Response What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis A Prospective Study of Diagnostic Accuracy of Ultrasound Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis A Multi-omics Study of Adenomyosis Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Levonorgestrel Intrauterine System and Adenomyosis Validation of the Adenomyosis Calculator Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Norwegian Adenomyosis Study III: Peristalsis Histopathological Diagnosis of Adenomyosis Norwegian Adenomyosis Study I Vaginal Bromocriptine for Treatment of Adenomyosis Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis

Brief Title

LNG-IUS for Treatment of Dysmenorrhea

Official Title

Levonorgestrel-releasing Intrauterine System Compared to Low Dose Combined Oral Contraceptive Pills for Treatment of Adenomyosis: a Randomized Controlled Trial

Brief Summary

      Adenomyosis is a disease entity diagnosed when endometrial glands and stroma deep in the
      myometrium are associated with surrounding myometrial hypertrophy. The finding classically
      associated with adenomyosis is excessive uterine bleeding accompanied by worsening
      dysmenorrhea. The advent of endovaginal US has substantially improved the ability to diagnose
      adenomyosis. Different US features of adenomyosis have been reported, including uterine
      enlargement not explainable by the presence of leiomyomas, asymmetric thickening of the
      anterior or posterior myometrial wall, lack of contour abnormality or mass effect,
      heterogeneous poorly circumscribed areas within the myometrium, anechoic lacunae or cysts of
      varying sizes, and increased echotexture of the myometrium.

      Transvaginal power Doppler application is useful in studying the vascular tree of adenomyosis
      and can aid clinicians in planning the most appropriate therapeutic strategy. The
      differential diagnosis using power Doppler sonography is based on vascular characteristics.
      Adenomyosis is characterized by a preserved vascular texture supply that results in dilated
      spiral arteries running perpendicular toward the myometrium into the endometrial surface.
      Leiomyomata exhibits a vascular tree that typically circumscribes the solid mass. 2D
      transvaginal power Doppler angiography should be used to improve diagnostic sensitivity and
      facilitate appropriate therapeutic intervention.

      The levonorgestrel-releasing intrauterine system (IUS), Mirena, has been approved in Europe
      for contraception since 1990. Because of the suppressive effect of levonorgestrel on the
      endometrium, Mirena has also been proven to be effective for the management of menorrhagia
      and dysmenorrhea, and as a progestin component in postmenopausal hormone therapy. It was
      introduced in Taiwan in 1995 as an alternative therapy for idiopathic menorrhagia. Many cases
      of menorrhagia are caused by adenomyosis, and Mirena was, therefore, introduced for the
      treatment of adenomyosis in Taiwan.

      The current study is designed to evaluate the best treatment modality for treatment of
      adenomyosis clinical by assessment of dysmenorrhea and or chronic pelvic pain by visual
      analogue scale and menstrual blood loss by menstrual diary, imaging by ultrasound and Doppler

Study Phase

Phase 2

Study Type


Primary Outcome

Visual analogue score (VAS) for dysmenorrhea or chronic pelvic pain will be measure before after use LNG_IUS and COCs.

Secondary Outcome

 Menstrual blood loss: assessment of blood loss, measured at the beginning of intervention and for 3 months





Study Arms / Comparison Groups

 LNG-IUS (Mirena)
Description:  Group I "the LNG-IUS group" where they will have a LNG IUS (mirena) inserted for them


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

April 2012

Completion Date

April 2015

Primary Completion Date

April 2013

Eligibility Criteria

        Inclusion Criteria:

          1. Women have dysmenorrhoea and/or chronic pelvic pain secondary to adenomyosis.

          2. Planning for birth spacing for at least 2 years.

          3. Patient aged between 20-45 years old.

          4. Ultrasonographic and Doppler examination suggestive of adenomyosis.

          5. Living in a nearby area to make follow-up reasonably possible.

        Exclusion Criteria:

          1. Pregnancy

          2. Evidence of defective coagulation.

          3. History or evidence of malignancy.

          4. Hyperplasia in the endometrial biopsy.

          5. Incidental adnexal abnormality on ultrasound.

          6. Contraindications to COCs.

          7. Absolute contraindication of LNG-IUS insertion.

          8. Previous endometrial ablation or resection

          9. Uninvestigated postcoital bleeding

         10. Untreated abnormal cervical cytology




20 Years - 45 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


, , 

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Omar Mamdouh Shaaban

Study Sponsor

, , 

Verification Date

November 2017